435 related articles for article (PubMed ID: 16093979)
1. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer prevention and finasteride.
D'Amico AV; Barry MJ
J Urol; 2006 Nov; 176(5):2010-2; discussion 2012-3. PubMed ID: 17070238
[TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
4. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
5. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
8. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
9. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
[TBL] [Abstract][Full Text] [Related]
10. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
[TBL] [Abstract][Full Text] [Related]
11. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
Elliott CS; Shinghal R; Presti JC
Clin Cancer Res; 2009 Jul; 15(14):4694-9. PubMed ID: 19584168
[TBL] [Abstract][Full Text] [Related]
12. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
14. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
15. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
16. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
18. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
19. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
Reed AB; Parekh DJ
Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
[TBL] [Abstract][Full Text] [Related]
20. The influence of statin medications on prostate-specific antigen levels.
Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
